Abstract
The wide-ranging field of cognition enhancing research along with its ethics as it stands today is summarized. In the forefront are potentially novel drugs and non-pharmacological treatments for cognitive impairment across many different psychiatric and neurologic indications. Today’s research will bring new drugs to patients tomorrow, and tomorrow’s research will bring new molecular targets to clinical development that should be cognitive domain-specific. There is the likelihood that special populations may be better treated and that personalized medicine for cognitive impairment could become a reality. It is conceivable that with the current research effort, cognition enhancing drugs will become available to wide-ranging populations of people with neuropsychiatric illness and to those that are healthy. In some cultures, there is a push in society to be more intelligent or have more cognitive prowess. Thus, the ethical use of cognitive enhancing drugs should be an area of debate and communication. Neuroethics is a growing field and it intends to bring together key contributors such as physicians, disease experts, regulatory officials, and policy makers to discuss how such medicines can or should be made available. Together with this, one has to consider the possibility that no single medicine or technology will have a great impact on cognition and, therefore, combination therapy of drugs plus other approaches like exercise or transcranial direct-current stimulation may be the path forward. This is another area of scientific inquiry and debate, and the results should be fruitful and helpful to patients. The science of cognition is advancing at a rapid rate, and communication of its progress along with the development of rational and ethical policies for use of cognitive enhancers will be beneficial.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ball N, Wolbring G (2014) Cognitive enhancement: perceptions among parents of children with disabilities. Neuroethics 7:345–364
Banjo OC, Nadler R, Reiner PB (2010) Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS One 5:e14322
Cabrera LY (2015) How does enhancing cognition affect human values? How does this translate into social responsibility? Curr Top Behav Neurosci 19:223–241, Epub ahead of print July 22, 2014
Callahan PM, Terry AV (2015) Attention. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
CenterWatch. A clinical trials and drug information resource website. www.centerwatch.com
Costa V, Lugert S, Jagasia R (2015) Role of adult hippocampal neurogenesis in cognition in physiology and disease: pharmacological targets and biomarkers. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Di Pietro NC, Illes J (2013) Disclosing incidental findings in brain research: the rights of minors in decision-making. J Magn Reson Imaging 38:1009–1013
Fernandez F, Reeves RH (2015) Assessing cognitive improvement in people with Down syndrome: important considerations for drug efficacy trials. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Forlini C, Hall W, Maxwell B, Outram SM, Reiner PB, Repantis D, Schermer M, Racine E (2013) Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. EMBO Rep 14:123–128
Harvey PD, Keefe RSE (2015) Methods for delivering and evaluating the efficacy of cognitive enhancement. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Kelly AM (2015) Non-pharmacological approaches to cognitive enhancement. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Kondabolu K, Kowalski MM, Roberts EA, Han X (2015) Optogenetics and deep brain stimulation neurotechnologies. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Ménard C, Gaudreau P, Quirion R (2015) Signaling pathways relevant to cognition-enhancing drug targets. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141–168
Mohamed AD, Sahakian BJ (2012) The ethics of elective psychopharmacology. Int J Neuropsychopharmacol 15:559–571
Nader K (2015) Emotional Memory. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Patin A, Hurlemann R (2015) Social cognition. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Riedel WJ, Blokland A (2015) Declarative memory. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Sahakian BJ, Morein-Zamir S (2011) Neuroethical issues in cognitive enhancement. J Psychopharmacol 25:197–204
Scott NA, Murphy TH, Illes J (2012) Incidental findings in neuroimaging research: a framework for anticipating the next frontier. J Empir Res Hum Res Ethics 7:53–57
Shook JR, Galvagni L, Giordano J (2014) Cognitive enhancement kept within contexts: neuroethics and informed public policy. Front Syst Neurosci 8:228
Sumiyoshi T (2015) Verbal memory. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Talpos J, Shoaib M (2015) Executive function. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Taylor JR, Torregrossa MM (2015) Pharmacological disruption of maladaptive memory. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Vahabzadeh A, Landino SM, Finger BC, Carlezon WA Jr, McDougle CJ (2015) Neural targets in the study and treatment of social-cognition in autism spectrum disorder. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Wade L, Forlini C, Racine E (2014) Generating genius: how an Alzheimer’s drug became considered a ‘cognitive enhancer’ for healthy individuals. BMC Med Ethics 15:37
Wallace TL, Ballard TM, Glavis-Bloom C (2015) Animal paradigms of cognitive enhancement with translation to humans. In: Kantak KM, Wettstein JG (eds) Cognitive enhancement. Springer, Cham
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kantak, K.M., Wettstein, J.G. (2015). Closing Thoughts for Cognitive Enhancement. In: Kantak, K., Wettstein, J. (eds) Cognitive Enhancement. Handbook of Experimental Pharmacology, vol 228. Springer, Cham. https://doi.org/10.1007/978-3-319-16522-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-16522-6_16
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16521-9
Online ISBN: 978-3-319-16522-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)